Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 14/20 | 0.54 |
| ▸ | FADS1 | O60427 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2322579 | 1.00 | GRM2 (0.54) | GRM2FADS1F10SMN1; SMN2 | |
| SCHEMBL4669702 | 1.00 | GRM2 (0.54) | GRM2FADS1F10SMN1; SMN2 | |
| SCHEMBL5762328 | 0.88 | GRM2 (0.53) | GRM2FADS1F10 | |
| SCHEMBL12635405 | 0.87 | GRM2 (0.51) | GRM2FADS1F10 | |
| SCHEMBL4669143 | 0.84 | L3MBTL1 (0.48) | GRM2F10 | |
| SCHEMBL4669144 | 0.84 | L3MBTL1 (0.48) | GRM2F10 | |
| SCHEMBL4637383 | 0.84 | FADS1 (0.60) | GRM2FADS1 | |
| SCHEMBL4637380 | 0.84 | FADS1 (0.60) | GRM2FADS1 | |
| SCHEMBL7461978 | 0.82 | MAOA (0.44) | GRM2F10 | |
| SCHEMBL7460584 | 0.82 | GRM2 (0.52) | GRM2FADS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117777121-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| CN-110099898-B | Compounds and uses thereof | 优曼尼蒂治疗公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
| WO-2018081167-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2018-05-03 | — | — | WO | disclosed |
| EP-1937655-A1 | HIV-1 PROTEASE INHIBITORS, AND METHODS OF MAKING AND USING THEM | University of Massachusetts (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007002173-A1 | HIV-1 PROTEASE INHIBITORS, AND METHODS OF MAKING AND USING THEM | UNIVERSITY OF MASSACHUSETTS (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | GRM2 194/4885FADS1 1990/4885F10 2476/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | GRM2 194/4885FADS1 1990/4885F10 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.